Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity

NCT06131372 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT06131372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06131372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
April 1, 2024
Completion date
November 6, 2025
Enrollment
626 (actual)
Sites
129

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, obesity, type 2 diabetes